Baclofen and the risk of fall and fracture in older adults: A real-world cohort study
- PMID: 37933734
- PMCID: PMC10872960
- DOI: 10.1111/jgs.18665
Baclofen and the risk of fall and fracture in older adults: A real-world cohort study
Abstract
Background: The growth of oral muscle relaxant prescriptions among older adults in the United States is concerning due to the drugs' adverse sedative effects. Baclofen is a gamma-aminobutyric acid agonist muscle relaxant that is associated with encephalopathy. We characterized the risk of fall and fracture associated with oral baclofen against other muscle relaxants (tizanidine or cyclobenzaprine) in older adults.
Methods: We designed a new-user, active-comparator study using tertiary health system data from Geisinger Health, Pennsylvania (January 2005 through December 2018). Older adults (aged ≥65 years) newly treated with baclofen, tizanidine, or cyclobenzaprine were included. Propensity score-based inverse probability of treatment weighting (IPTW) was used to balance the treatment groups on 58 baseline characteristics. Fine-Gray competing risk regression was used to estimate the risk of fall and fracture.
Results: The study cohort comprised of 2205 new baclofen users, 1103 new tizanidine users, and 9708 new cyclobenzaprine users. During a median follow-up of 100 days, baclofen was associated with a higher risk of fall compared to tizanidine (IPTW incidence rate, 108.4 vs. 61.9 per 1000 person-years; subdistribution hazard ratio [SHR], 1.68 [95% CI, 1.20-2.36]). The risk of fall associated with baclofen was comparable to cyclobenzaprine (SHR, 1.17 [95% CI, 0.93-1.47]) with a median follow-up of 106 days. The risk of fracture was similar among patients treated with baclofen versus tizanidine (SHR, 0.85 [95% CI, 0.63-1.14]) or cyclobenzaprine (SHR, 0.85 [95% CI, 0.67-1.07]).
Conclusions: The risk of fall associated with baclofen was greater than tizanidine, but not compared to cyclobenzaprine in older adults. The risk of fracture was comparable among the older users of baclofen, tizanidine, and cyclobenzaprine. Our findings may inform risk-benefit considerations in the increasingly common clinical encounters where oral muscle relaxants are prescribed.
Keywords: baclofen; fall; fracture; muscle relaxant.
© 2023 The American Geriatrics Society.
Conflict of interest statement
Conflict of Interest
Authors have no relevant disclosures.
Similar articles
-
Baclofen and the Risk of Encephalopathy: A Real-World, Active-Comparator Cohort Study.Mayo Clin Proc. 2023 May;98(5):676-688. doi: 10.1016/j.mayocp.2022.11.004. Epub 2023 Apr 5. Mayo Clin Proc. 2023. PMID: 37028980 Free PMC article.
-
Safety of baclofen versus tizanidine for older adults with musculoskeletal pain.J Am Geriatr Soc. 2023 Aug;71(8):2579-2584. doi: 10.1111/jgs.18349. Epub 2023 Mar 29. J Am Geriatr Soc. 2023. PMID: 36989193
-
Baclofen and Tizanidine Adverse Effects Observed Among Community-Dwelling Adults Above the Age of 50 Years: A Systematic Review.Ann Pharmacother. 2024 May;58(5):523-532. doi: 10.1177/10600280231193080. Epub 2023 Aug 17. Ann Pharmacother. 2024. PMID: 37589096 Review.
-
Comparative Risk of Opioid Overdose With Concomitant Use of Prescription Opioids and Skeletal Muscle Relaxants.Neurology. 2022 Sep 27;99(13):e1432-e1442. doi: 10.1212/WNL.0000000000200904. Epub 2022 Jul 14. Neurology. 2022. PMID: 35835561
-
Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.J Pain Symptom Manage. 2004 Aug;28(2):140-75. doi: 10.1016/j.jpainsymman.2004.05.002. J Pain Symptom Manage. 2004. PMID: 15276195 Review.
Cited by
-
Tizanidine: Advances in Pharmacology & Therapeutics and Drug Formulations.J Pain Res. 2024 Mar 21;17:1257-1271. doi: 10.2147/JPR.S461032. eCollection 2024. J Pain Res. 2024. PMID: 38529017 Free PMC article. Review.
References
-
- ClinCalc LLC. The Top 200 Drugs of 2020 [Internet]. 2021. [cited 2023 Jun 28];Available from: https://clincalc.com/DrugStats/
-
- U.S. Food and Drug Administration. OZOBAX (baclofen) oral solution [Internet]. 2019. [cited 2022 Jan 21];Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208193s000lbl.pdf
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
